NICOX SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.374 EUR | -0.27% |
|
-1.84% | -15.38% |
| Apr. 22 | Nicox: cash position of 9.1 million euros at the end of March | CF |
| Feb. 28 | Nicox, BlackRock Sign Deal for Debt Restructuring | MT |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -15.38% | 19.97M | - | ||
| +5.31% | 70.44B | A | ||
| +10.97% | 8.94B | A- | ||
| -16.83% | 4.75B | A- | ||
| +43.48% | 4.5B | - | ||
| +3.20% | 3.85B | B- | ||
| +18.82% | 2.38B | B | ||
| -21.36% | 2.34B | C- | ||
| -29.67% | 2.2B | - | ||
| +8.38% | 1.96B | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ALCOX Stock
- Ratings Nicox SA
